Deep Apple Therapeutics CEO Spiros Liras (L) and interim CSO Paul Da Silva Jardine

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Two for­mer chem­istry VPs who worked at Pfiz­er’s car­dio­vas­cu­lar and meta­bol­ic re­search group have come to­geth­er to build a new biotech as the obe­si­ty drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.